Two Sigma Securities LLC Acquires 1,645 Shares of IDEXX Laboratories, Inc. $IDXX

Two Sigma Securities LLC grew its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 166.0% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,636 shares of the company’s stock after purchasing an additional 1,645 shares during the quarter. Two Sigma Securities LLC’s holdings in IDEXX Laboratories were worth $1,388,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of IDXX. Harbour Investments Inc. boosted its stake in shares of IDEXX Laboratories by 13.3% during the fourth quarter. Harbour Investments Inc. now owns 136 shares of the company’s stock valued at $92,000 after purchasing an additional 16 shares in the last quarter. Pinnacle Associates Ltd. lifted its holdings in IDEXX Laboratories by 1.5% during the fourth quarter. Pinnacle Associates Ltd. now owns 1,227 shares of the company’s stock worth $830,000 after buying an additional 18 shares during the period. Triad Wealth Partners LLC increased its holdings in shares of IDEXX Laboratories by 3.1% in the 1st quarter. Triad Wealth Partners LLC now owns 600 shares of the company’s stock valued at $337,000 after acquiring an additional 18 shares during the period. Advisory Services Network LLC lifted its stake in shares of IDEXX Laboratories by 2.5% during the 4th quarter. Advisory Services Network LLC now owns 752 shares of the company’s stock worth $509,000 after purchasing an additional 18 shares during the last quarter. Finally, KCM Investment Advisors LLC boosted its position in IDEXX Laboratories by 5.3% during the fourth quarter. KCM Investment Advisors LLC now owns 377 shares of the company’s stock valued at $255,000 after purchasing an additional 19 shares in the last quarter. Hedge funds and other institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Price Performance

NASDAQ IDXX opened at $556.69 on Tuesday. The company has a market cap of $43.86 billion, a price-to-earnings ratio of 39.15, a PEG ratio of 2.96 and a beta of 1.54. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.17 and a quick ratio of 0.87. The stock’s fifty day moving average price is $559.23 and its 200 day moving average price is $572.70. IDEXX Laboratories, Inc. has a 1 year low of $518.55 and a 1 year high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Tuesday, August 4th. The company reported $4.27 EPS for the quarter, topping analysts’ consensus estimates of $3.94 by $0.33. The company had revenue of $1.22 billion during the quarter, compared to analysts’ expectations of $1.20 billion. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%.The firm’s revenue was up 9.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $3.50 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. As a group, equities research analysts forecast that IDEXX Laboratories, Inc. will post 14.81 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. Weiss Ratings downgraded shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a report on Thursday. Citigroup raised their price target on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the company a “neutral” rating in a report on Wednesday, August 5th. UBS Group boosted their price objective on shares of IDEXX Laboratories from $620.00 to $670.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 5th. Barclays decreased their target price on shares of IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating for the company in a research report on Tuesday, August 11th. Finally, Wall Street Zen downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Six research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $747.00.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.